Exploring A One-Stop Integrated Solution For AAV Vector Clinical Production

Source: Catalent
Viral Safety In Monoclonal Antibody Manufacturing-Getty-184714532

Every choice is critical in adeno-associated virus (AAV) vector production. Make the right choices and you can slash time to manufacture clinical-quality drug product to just nine months, but missteps can cause timelines and costs to spiral, delaying access to life-changing medicines and handing advantages to rivals.

In this webinar, we show you how to make the right choices across all the key variables, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods. Viewers will gain a blueprint for a complete platform approach that is consistent, efficient and delivers a process that easily scales up as you move to late-stage GMP production and on the market.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online